| Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales,
operating profit, depreciation and amortization, interest expense,
income tax benefit (expense) and other comprehensive income for the
three months and six months ended May 31, 2017:
|
|
|
|
|
|
|
|
|
| |
|
For the three months
ended May 31, 2017 |
|
|
For the six months
ended May 31, 2017 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
6,174,896 |
|
|
$ |
11,786,720 |
|
|
PrepaCyte®-CB
|
|
|
61,855 |
|
|
|
226,655 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
6,236,751 |
|
|
$ |
12,013,375 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,517,078 |
|
|
$ |
2,909,873 |
|
|
PrepaCyte®-CB
|
|
|
74,888 |
|
|
|
198,190 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
1,591,966 |
|
|
$ |
3,108,063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
22,873 |
|
|
$ |
45,439 |
|
|
PrepaCyte®-CB
|
|
|
9,063 |
|
|
|
18,127 |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
31,936 |
|
|
$ |
63,566 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,214,346 |
|
|
$ |
2,298,038 |
|
|
PrepaCyte®-CB
|
|
|
(22,096 |
) |
|
|
10,338 |
|
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
1,192,250 |
|
|
$ |
2,308,376 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
325,314 |
|
|
$ |
622,358 |
|
|
PrepaCyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
325,314 |
|
|
$ |
622,358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(331,737 |
) |
|
$ |
(637,454 |
) |
|
PrepaCyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax expense
|
|
$ |
(331,737 |
) |
|
$ |
(637,454 |
) |
|
|
|
|
|
|
|
|
|
The following table shows the assets by segment as of May 31,
2017 and November 30, 2016:
|
|
|
|
|
|
|
|
|
| |
|
As of May 31, 2017 |
|
|
As of November 30,
2016 |
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
20,562,496 |
|
|
$ |
18,960,261 |
|
|
PrepaCyte®-CB
|
|
|
474,121 |
|
|
|
578,207 |
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
21,036,617 |
|
|
$ |
19,538,468 |
|
|
|
|
|
|
|
|
|
|
The following table shows, by segment: net revenue, cost of sales,
operating profit, depreciation and amortization, interest expense,
income tax benefit (expense) and other comprehensive income for the
three months and six months ended May 31, 2016:
|
|
|
|
|
|
|
|
|
| |
|
For the three months
ended May 31, 2016 |
|
|
For the six months
ended May 31, 2016 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
5,706,677 |
|
|
$ |
10,727,136 |
|
|
PrepaCyte®-CB
|
|
|
66,379 |
|
|
|
198,118 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
5,773,056 |
|
|
$ |
10,925,254 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,345,370 |
|
|
$ |
2,590,393 |
|
|
PrepaCyte®-CB
|
|
|
85,730 |
|
|
|
188,998 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
1,431,100 |
|
|
$ |
2,779,391 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
28,555 |
|
|
$ |
57,233 |
|
|
PrepaCyte®-CB
|
|
|
13,317 |
|
|
|
26,187 |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
41,872 |
|
|
$ |
83,420 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
915,052 |
|
|
$ |
1,056,069 |
|
|
PrepaCyte®-CB
|
|
|
(32,668 |
) |
|
|
(17,263 |
) |
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
882,384 |
|
|
$ |
1,038,806 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
335,589 |
|
|
$ |
582,532 |
|
|
PrepaCyte®-CB
|
|
|
7,874 |
|
|
|
22,265 |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
343,463 |
|
|
$ |
604,797 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(201,735 |
) |
|
$ |
(201,735 |
) |
|
PrepaCyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income expense
|
|
$ |
(201,735 |
) |
|
$ |
(201,735 |
) |
|
|
|
|
|
|
|
|
|
|